Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 20/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.71 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.71 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.71 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.71 |
| ▸ | RET | P07949 | 1/20 | 0.71 |
| ▸ | HCK | P08631 | 1/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.71 |
| ▸ | FLT4 | P35916 | 1/20 | 0.71 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.71 |
| ▸ | SIK1 | P57059 | 1/20 | 0.71 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.71 |
| ▸ | WNK3 | Q9BYP7 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2486949 | 0.90 | AURKA (1.00) | AURKAAURKB | |
| SCHEMBL13273318 | 0.88 | AURKA (1.00) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL2485592 | 0.88 | AURKA (1.00) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL13273317 | 0.87 | AURKA (1.00) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL2486959 | 0.87 | AURKA (1.00) | AURKAAURKB | |
| SCHEMBL2486421 | 0.85 | AURKA (1.00) | AURKAAURKB | |
| SCHEMBL2483923 | 0.85 | AURKA (1.00) | AURKAAURKB | |
| SCHEMBL3454160 | 0.83 | AURKA (1.00) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL2486354 | 0.82 | AURKA (1.00) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL2484787 | 0.82 | AURKA (1.00) | AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367821-B1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2015-09-16 | — | — | EP | claimed |
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | MERCK PATENT GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| EP-2367821-A1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | claimed |
| WO-2010077530-A1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2010-07-08 | — | — | WO | claimed |
| US-9938268-B2 | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2018-04-10 | — | — | US | disclosed |
| US-9938268-B2 | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2018-04-10 | — | — | US | disclosed |
| US-9938268-B2 | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2018-04-10 | — | — | US | disclosed |
| EP-2367821-B1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2015-09-16 | — | — | EP | disclosed |
| EP-2367821-B1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | MERCK PATENT GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | MERCK PATENT GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | MERCK PATENT GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2010077530-A1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | PRKCB, PNCK, PACSIN2 | AURKA 562/4885AURKB 440/4885MAPK13 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.